Skip to main content

Advertisement

SpringerLink
Log in

Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors

  • Symposium - Osteosarcoma
  • Published:
Indian Journal of Orthopaedics Aims and scope Submit manuscript

Abstract

Osteosarcoma (OS), the commonest malignancy of osteoarticular origin, is a very aggressive neoplasm. Divergent histologic differentiation is common in OS; hence triple diagnostic approach is essential in all cases. 20% cases are atypical owing to lack of concurrence among clinicoradiologic and pathologic features necessitating resampling. Recognition of specifi c anatomic and histologic variants is essential in view of better outcome. Traditional prognostic factors of OS do stratify patients for short term outcome, but often fail to predict their long term outcome. Considering the negligible improvement in the patient outcome during the last 20 years, search for novel prognostic factors is in progress like ezrin vascular endothelial growth factor, chemokine receptors, dysregulation of various micro ribonucleic acid are potentially promising. Their utility needs to be validated by long term followup studies before they are incorporated in routine clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mirra JM, Gold RH, Picci P. Osseous tumors of intranedullary origin. In: Mirra JM, Picci P, Gold RH, editors. Bone Tumors. Clinical, Radiologic and Pathologic Correlations. Philadelphia: Lea and Febiger Publishers; 1989. p. 143–438.

    Google Scholar 

  2. Fechner RE, Mills SE. Atlas of Tumor Pathology. Tumors of the Bones and Joints. Washington DC: Armed Forces Institute of Pathology; 1992.

    Google Scholar 

  3. Broadhead ML, Clark JC, Myers DE, Dass CR, Choong PF. The molecular pathogenesis of osteosarcoma: A review. Sarcoma 2011;2011:959248.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006;106:1154–61.

    Article  PubMed  Google Scholar 

  5. Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, et al. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012;2012:704872.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Klein MJ, Siegal GP. Osteosarcoma: Anatomic and histologic variants. Am J Clin Pathol 2006;125:555–81.

    Article  PubMed  Google Scholar 

  7. Bentzen SM, Poulsen HS, Kaae S, Jensen OM, Johansen H, Mouridsen HT, et al. Prognostic factors in osteosarcomas. A regression analysis. Prognostic factors in osteosarcomas 1988;62:194–202.

    CAS  Google Scholar 

  8. Conner JR, Hornick JL. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours. Histopathology 2013;63:36–49.

    Article  PubMed  Google Scholar 

  9. Yen CH, Chang CY, Teng MM, Wu HT, Chen PC, Chiou HJ, et al. Different and identical features of chondroblastic osteosarcoma and chondrosarcoma: Highlights on radiography and magnetic resonance imaging. J Chin Med Assoc 2009;72:76–82.

    Article  PubMed  Google Scholar 

  10. Akpolat N, Yildirim H, Poyraz K. Sacral chondroblastic osteosarcoma misdiagnosed as chondrosarcoma and chordoma. Turk J Med Sci 2007;37:243–9.

    Google Scholar 

  11. Unni KK. Cartilaginous lesions of bone. J Orthop Sci 2001;6:457–72.

    Article  CAS  PubMed  Google Scholar 

  12. Gomez-Brouchet A, Mourcin F, Gourraud PA, Bouvier C, De Pinieux G, Le Guelec S, et al. Galectin-1 is a powerful marker to distinguish chondroblastic osteosarcoma and conventional chondrosarcoma. Hum Pathol 2010;41:1220–30.

    Article  CAS  PubMed  Google Scholar 

  13. Unni KK, Inwards CY. Fibrosarcoma and desmoplastic fibroma. In: Dahlin’s Bone Tumors: General Aspects and Data on 10,165 Cases. 6th ed. Republic of China: Lippincott Williams and Wilkins; 2010. p. 169–78.

    Google Scholar 

  14. Wang CS, Yin QH, Liao JS, Lou JH, Ding XY, Zhu YB. Giant cell-rich osteosarcoma in long bones: Clinical, radiological and pathological features. Radiol Med 2013;118:1324–34.

    Article  PubMed  Google Scholar 

  15. Liu JJ, Liu S, Wang JG, Zhu W, Hua YQ, Sun W, et al. Telangiectatic osteosarcoma: A review of literature. Onco Targets Ther 2013;6:593–602.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Machado I, López Guerrero JA, Navarro S, Mayordomo E, Scotlandi K, Picci P, et al. Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma. Virchows Arch 2013;462:665–71.

    Article  CAS  PubMed  Google Scholar 

  17. D’cruze L, Dutta R, Rao S, Anuradha R, Varadarajan S, Kuruvilla S. The role of immunohistochemistry in the analysis of the spectrum of small round cell tumours at a tertiary care centre. J Clin Diagn Res 2013;7:1377–82.

    PubMed  PubMed Central  Google Scholar 

  18. Puri A, Jaffe N, Gelderblom H. Osteosarcoma: Lessons learned and future avenues. Sarcoma 2013;2013:641687.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Dujardin F, Binh MB, Bouvier C, Gomez-Brouchet A, Larousserie F, Muret Ad, et al. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol 2011;24:624–37.

    Article  CAS  PubMed  Google Scholar 

  20. Yoshida A, Ushiku T, Motoi T, Shibata T, Beppu Y, Fukayama M, et al. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol 2010;23:1279–88.

    Article  CAS  PubMed  Google Scholar 

  21. Papathanassiou ZG, Alberghini M, Thiesse P, Gambarotti M, Bianchi G, Tranfaglia C, et al. Parosteal osteosarcoma mimicking osteochondroma: A radio-histologic approach on two cases. Clin Sarcoma Res 2011;1:2.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Cesari M, Alberghini M, Vanel D, Palmerini E, Staals EL, Longhi A, et al. Periosteal osteosarcoma: A single-institution experience. Cancer 2011;117:1731–5.

    Article  PubMed  Google Scholar 

  23. Dodd LG, Scully SP, Cothran RL, Harrelson JM. Utility of fine-needle aspiration in the diagnosis of primary osteosarcoma. Diagn Cytopathol 2002;27:350–3.

    Article  PubMed  Google Scholar 

  24. Koscick RL, Petersilge CA, Makley JT, Abdul-Karim FW. CT-guided fine needle aspiration and needle core biopsy of skeletal lesions. Complementary diagnostic techniques. CT-guided fine needle aspiration and needle core biopsy of skeletal lesions 1998;42:697–702.

    CAS  Google Scholar 

  25. van der Bijl AE, Taminiau AH, Hermans J, Beerman H, Hogendoorn PC. Accuracy of the Jamshidi trocar biopsy in the diagnosis of bone tumors. Clin Orthop Relat Res 1997;334:233–43.

    Google Scholar 

  26. Tsukushi S, Nishida Y, Yamada Y, Yoshida M, Ishiguro N. CT-guided needle biopsy for musculoskeletal lesions. Arch Orthop Trauma Surg 2010;130:699–703.

    Article  PubMed  Google Scholar 

  27. den Heeten GJ, Oldhoff J, Oosterhuis JW, Schraffordt Koops H. Biopsy of bone tumours. J Surg Oncol 1985;28:247–51.

    Article  Google Scholar 

  28. Iwata S, Ishii T, Kawai A, Hiruma T, Yonemoto T, Kamoda H, et al. Prognostic factors in elderly osteosarcoma patients: A multiinstitutional retrospective study of 86 cases. Ann Surg Oncol 2014;21:263–8.

    Article  PubMed  Google Scholar 

  29. Grimer RJ, Cannon SR, Taminiau AM, Bielack S, Kempf-Bielack B, Windhager R, et al. Osteosarcoma over the age of forty. Eur J Cancer 2003;39:157–63.

    Article  CAS  PubMed  Google Scholar 

  30. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776–90.

    Article  PubMed  Google Scholar 

  31. Pakos EE, Nearchou AD, Grimer RJ, Koumoullis HD, Abudu A, Bramer JA, et al. Prognostic factors and outcomes for osteosarcoma: An international collaboration. Eur J Cancer 2009;45:2367–75.

    Article  PubMed  Google Scholar 

  32. Hansen MF, Seton M, Merchant A. Osteosarcoma in Paget’s disease of bone. J Bone Miner Res 2006;21 Suppl 2:P58–63.

    Article  Google Scholar 

  33. Shaylor PJ, Peake D, Grimer RJ, Carter SR, Tillman RM, Spooner D. Paget’s Osteosarcoma-no Cure in Sight. Sarcoma 1999;3:191–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Ferrari S, Bertoni F, Mercuri M, Picci P, Giacomini S, Longhi A, et al. Predictive factors of disease-free survival for nonmetastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol 2001;12:1145–50.

    Article  CAS  PubMed  Google Scholar 

  35. Scranton PE Jr, DeCicco FA, Totten RS, Yunis EJ. Prognostic factors in osteosarcoma. A review of 20 year’s experience at the University of Pittsburgh Health Center Hospitals. Prognostic factors in osteosarcoma 1975;36:2179–91.

    Google Scholar 

  36. Petrilli AS, Gentil FC, Epelman S, Lopes LF, Bianchi A, Lopes A, et al. Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer 1991;68:733–7.

    Article  CAS  PubMed  Google Scholar 

  37. Smeland S, Müller C, Alvegard TA, Wiklund T, Wiebe T, Björk O, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: Prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003;39:488–94.

    Article  CAS  PubMed  Google Scholar 

  38. Szendroi M, Pápai Z, Koós R, Illés T. Limb-saving surgery, survival, and prognostic factors for osteosarcoma: The Hungarian experience. J Surg Oncol 2000;73:87–94.

    Article  CAS  PubMed  Google Scholar 

  39. Petrilli AS, de Camargo B, Filho VO, Bruniera P, Brunetto AL, Jesus-Garcia R, et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: Prognostic factors and impact on survival. J Clin Oncol 2006;24:1161–8.

    Article  PubMed  Google Scholar 

  40. Zuo D, Zheng L, Sun W, Hua Y, Cai Z. Pathologic fracture does not influence prognosis in stage IIB osteosarcoma: A case-control study. World J Surg Oncol 2013;11:148.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Colomina J, Peiro A, Trullols L, Garcia I. Telangiectatic osteosarcoma. J Orthop Surg (Hong Kong) 2013;21:96–9.

    Article  Google Scholar 

  42. Miwa S, Takeuchi A, Shirai T, Taki J, Yamamoto N, Nishida H, et al. Prognostic value of radiological response to chemotherapy in patients with osteosarcoma. PLoS One 2013;8:e70015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Katonis P, Datsis G, Karantanas A, Kampouroglou A, Lianoudakis S, Licoudis S, et al. Spinal osteosarcoma. Clin Med Insights Oncol 2013;7:199–208.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Feng D, Yang X, Liu T, Xiao J, Wu Z, Huang Q, et al. Osteosarcoma of the spine: Surgical treatment and outcomes. World J Surg Oncol 2013;11:89.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Mukherjee D, Chaichana KL, Gokaslan ZL, Aaronson O, Cheng JS, McGirt MJ. Survival of patients with malignant primary osseous spinal neoplasms: Results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003. J Neurosurg Spine 2011;14:143–50.

    Article  PubMed  Google Scholar 

  46. Paparella ML, Olvi LG, Brandizzi D, Keszler A, Santini-Araujo E, Cabrini RL. Osteosarcoma of the jaw: An analysis of a series of 74 cases. Histopathology 2013;63:551–7.

    PubMed  Google Scholar 

  47. van den Berg H, Schreuder WH, de Lange J. Osteosarcoma: A comparison of jaw versus nonjaw localizations and review of the literature. Sarcoma 2013;2013:316123.

    PubMed  PubMed Central  Google Scholar 

  48. Dai X, Ma W, He X, Jha RK. Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing’s sarcoma. Med Sci Monit 2011;17:RA177–190.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Osborne TS, Khanna C. A review of the association between osteosarcoma metastasis and protein translation. J Comp Pathol 2012;146:132–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Jeon DG, Song WS, Kong CB, Cho WH, Cho SH, Lee JD, et al. Role of surgical margin on local recurrence in high risk extremity osteosarcoma: A case-controlled study. Clin Orthop Surg 2013;5:216–24.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Göbel V, Jürgens H, Etspüler G, Kemperdick H, Jungblut RM, Stienen U, et al. Prognostic significance of tumor volume in localized Ewing’s sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol 1987;113:187–91.

    Article  PubMed  Google Scholar 

  52. Durnali A, Alkis N, Cangur S, Yukruk FA, Inal A, Tokluoglu S, et al. Prognostic factors for teenage and adult patients with high-grade osteosarcoma: An analysis of 240 patients. Med Oncol 2013;30:624.

    Article  PubMed  CAS  Google Scholar 

  53. Miwa S, Takeuchi A, Ikeda H, Shirai T, Yamamoto N, Nishida H, et al. Prognostic value of histological response to chemotherapy in osteosarcoma patients receiving tumor-bearing frozen autograft. PLoS One 2013;8:e71362.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: Pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977;101:14–8.

    CAS  PubMed  Google Scholar 

  55. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG. Primary osteogenic sarcoma: The rationale for preoperative chemotherapy and delayed surgery. Cancer 1979;43:2163–77.

    Article  CAS  PubMed  Google Scholar 

  56. Bacci G, Mercuri M, Longhi A, Ferrari S, Bertoni F, Versari M, et al. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with nonmetastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer 2005;41:2079–85.

    Article  CAS  PubMed  Google Scholar 

  57. Picci P, Bacci G, Campanacci M, Gasparini M, Pilotti S, Cerasoli S, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy 1985;56:1515–21.

    CAS  Google Scholar 

  58. Saeter G, Høie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim OP. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Systemic relapse of patients with osteogenic sarcoma 1995;75:1084–93.

    CAS  Google Scholar 

  59. Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003;98:2447–56.

    Article  PubMed  Google Scholar 

  60. PosthumaDeBoer J, Witlox MA, Kaspers GJ, van Royen BJ. Molecular alterations as target for therapy in metastatic osteosarcoma: A review of literature. Clin Exp Metastasis 2011;28:493–503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol 2013;25:398–406.

    Article  CAS  PubMed  Google Scholar 

  62. Li H, Min D, Zhao H, Wang Z, Qi W, Zheng S, et al. The prognostic role of ezrin immunoexpression in osteosarcoma: A meta-analysis of published data. PLoS One 2013;8:e64513.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Salas S, Bartoli C, Deville JL, Gaudart J, Fina F, Calisti A, et al. Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas. Virchows Arch 2007;451:999–1007.

    Article  CAS  PubMed  Google Scholar 

  64. Wang Z, He ML, Zhao JM, Qing HH, Wu Y. Meta-analysis of associations of the ezrin gene with human osteosarcoma response to chemotherapy and prognosis. Asian Pac J Cancer Prev 2013;14:2753–8.

    Article  PubMed  Google Scholar 

  65. Pignochino Y, Grignani G, Cavalloni G, Motta M, Tapparo M, Bruno S, et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2009;8:118.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  66. Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. Sarcomas in TP53 germline mutation carriers: A review of the IARC TP53 database. Cancer 2012;118:1387–96.

    Article  CAS  PubMed  Google Scholar 

  67. Fu HL, Shao L, Wang Q, Jia T, Li M, Yang DP. A systematic review of p53 as a biomarker of survival in patients with osteosarcoma. Tumour Biol 2013;34:3817–21.

    Article  CAS  PubMed  Google Scholar 

  68. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000;6:572–7.

    CAS  PubMed  Google Scholar 

  69. Chen D, Zhang YJ, Zhu KW, Wang WC. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma. Tumour Biol 2013;34:1895–9.

    Article  CAS  PubMed  Google Scholar 

  70. Qu JT, Wang M, He HL, Tang Y, Ye XJ. The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: A meta-analysis and systemic review. J Cancer Res Clin Oncol 2012;138:819–25.

    Article  CAS  PubMed  Google Scholar 

  71. Xu M, Xu CX, Bi WZ, Song ZG, Jia JP, Chai W, et al. Effects of endostar combined multidrug chemotherapy in osteosarcoma. Bone 2013;57:111–5.

    Article  CAS  PubMed  Google Scholar 

  72. Liao YX, Zhou CH, Zeng H, Zuo DQ, Wang ZY, Yin F, et al. The role of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of bone sarcomas (Review). Int J Mol Med 2013;32:1239–46.

    Article  CAS  PubMed  Google Scholar 

  73. Laverdiere C, Hoang BH, Yang R, Sowers R, Qin J, Meyers PA, et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 2005;11:2561–7.

    Article  CAS  PubMed  Google Scholar 

  74. Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH, et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 2008;25:201–11.

    Article  CAS  PubMed  Google Scholar 

  75. Poos K, Smida J, Nathrath M, Maugg D, Baumhoer D, Korsching E. How microRNA and transcription factor co-regulatory networks affect osteosarcoma cell proliferation. PLoS Comput Biol 2013;9:e1003210.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Zhou G, Shi X, Zhang J, Wu S, Zhao J. MicroRNAs in osteosarcoma: From biological players to clinical contributors, a review. J Int Med Res 2013;41:1–12.

    Article  CAS  PubMed  Google Scholar 

  77. Miao J, Wu S, Peng Z, Tania M, Zhang C. MicroRNAs in osteosarcoma: Diagnostic and therapeutic aspects. Tumour Biol 2013;34:2093–8.

    Article  CAS  PubMed  Google Scholar 

  78. Salinas-Souza C, De Oliveira R, Alves MT, Garcia Filho RJ, Petrilli AS, Toledo SR. The metastatic behavior of osteosarcoma by gene expression and cytogenetic analyses. Hum Pathol 2013;44:2188–98.

    Article  CAS  PubMed  Google Scholar 

  79. Wen X, Liu H, Yu K, Liu Y. Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: A meta-analysis. Tumour Biol 2014;35:845–8.

    Article  CAS  PubMed  Google Scholar 

  80. Jiao G, Ren T, Lu Q, Sun Y, Lou Z, Peng X, et al. Prognostic significance of cyclooxygenase-2 in osteosarcoma: A meta-analysis. Tumour Biol 2013;34:2489–95.

    Article  CAS  PubMed  Google Scholar 

  81. Zhou Y, Liu B, Wang M, Ni J. Endothelin-1 gene polymorphisms and risk of chemoresistant pediatric osteosarcoma. Pediatr Blood Cancer 2014;61:612–7.

    Article  PubMed  Google Scholar 

  82. Kubota D, Mukaihara K, Yoshida A, Tsuda H, Kawai A, Kondo T. Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma. J Proteomics 2013;91:393–404.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University College of Medical Sciences, University of Delhi, Shahdra, New Delhi, 110 095, India

    Neelam Wadhwa

Authors
  1. Neelam Wadhwa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neelam Wadhwa.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wadhwa, N. Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors. IJOO 48, 247–254 (2014). https://doi.org/10.4103/0019-5413.132497

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/0019-5413.132497

Key words

Search

Navigation